Psychosis and schizophrenia

NICE Pathways

Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject. Find out more about NICE Pathways.

• Coexisting severe mental illness and substance misuse: assessment and management in healthcare settings

• Coexisting severe mental illness and substance misuse: community health and social care services

• Psychosis and schizophrenia

NICE guidelines

Evidence-based recommendations on a range of health and care topics. Find out more about NICE guidelines

• Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings (CG120)

  Id:

  CG120

  Published date:

  March 2011

• Coexisting severe mental illness and substance misuse: community health and social care services (NG58)

  Id:

  NG58

  Published date:

  November 2016

• Psychosis and schizophrenia in adults: prevention and management (CG178)

  Id:

  CG178

  Published date:

  February 2014

• Psychosis and schizophrenia in children and young people: recognition and management (CG155)

  Id:

  CG155

  Published date:

  January 2013

Quality standards

Statements covering priority areas for quality improvement (including ways to measure quality). Find out more about Quality standards.

• Bipolar disorder, psychosis and schizophrenia in children and young people (QS102)

  Id:

  QS102

  Published date:

  October 2015

• Psychosis and schizophrenia in adults (QS80)

  Id:

  QS80

  Published date:

  February 2015

Technology appraisal guidance

Assessments of the clinical and cost effectiveness of health technologies (most commonly medicines, but also medical devices, procedures and diagnostic techniques). Find out more about Technology appraisals guidance.

• Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)

  Id:

  TA213

  Published date:

  January 2011

• Guidance on the use of electroconvulsive therapy (TA59)

  Id:

  TA59

  Published date:

  April 2003

• Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)

  Id:

  TA286

  Published date:

  May 2013

• Structural neuroimaging in first-episode psychosis (TA136)

  Id:

  TA136

  Published date:

  February 2008

Evidence summaries

Summaries of the best available evidence for selected new medicines, off-label use of licensed medicines and unlicensed medicines. Find out more about Evidence summaries.

• Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

  Id:

  ESNM39

  Published date:

  March 2014

• Schizophrenia: lurasidone (ESNM48)

  Id:

  ESNM48

  Published date:

  September 2014

• Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

  Id:

  ESUOM19

  Published date:

  September 2013

In development

• Coexisting severe mental illness and substance misuse

  New

  Yes

  Programme:

  Quality standard

  Expected publication date:

  TBC

New guidance and advice

Guidance and advice added since December 2017

• Coexisting severe mental illness and substance misuse

  New

  Yes

  Programme:

  Quality standard

  Expected publication date:

  TBC

  Status:

  In development

Register as a stakeholder

Stakeholders can comment on draft guidance and participate in workshops and events.

Register now